Lenalidomide induces degradation of IKZF1 and IKZF3

  • Oncoimmunology. 2014 Jul 3;3(7):e941742. doi: 10.4161/21624011.2014.941742.
Jan Krönke  1 ,  Slater N Hurst  1 ,  Benjamin L Ebert  1
Affiliations
  • 1. Brigham and Women's Hospital ; Boston, MA USA.
PMID: 25610725 DOI: 10.4161/21624011.2014.941742
Abstract

Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin Ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).

Keywords
lenalidomide; pomalidomide; thalidomide; ubiquitin.
Products